2025-12-19 - Analysis Report
Okay, let's break down the analysis of Johnson & Johnson (JNJ) based on the provided data.

**1) Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Johnson & Johnson is a diversified healthcare company with operations in pharmaceuticals, medical devices, and consumer health products.
*   **Cumulative Return:** JNJ (60.54%) vs. VOO (99.09%)
*   **Divergence:** Current divergence is -38.5%.
*   **Relative Divergence:** 32.9 (Indicates the current position when the minimum-maximum fluctuation range is set to 100).

**Analysis:**

*   JNJ has significantly underperformed the S&P 500 (VOO) in terms of cumulative return. The -38.5% divergence indicates that JNJ's growth has lagged the overall market represented by VOO.
*   A relative divergence of 32.9 suggests that, while the current divergence is negative, it's not at its worst historical level within the observed data period.  It's in the lower third of its divergence range.
*   The provided Alpha/Beta analysis shows generally negative Alpha values, indicating JNJ has underperformed relative to its risk-adjusted expected return compared to the market. Beta values are generally below 0.5, suggesting lower volatility than the market.
* Examining the year/year analysis, there appears to be a substantial downturn of CAGR, Alpha, and Beta values towards the end of the period.
* MDD is very high, suggesting a substantial risk of losses.

**Alpha, Beta Analysis Table & Explanation**

| Year       | CAGR    | MDD   | Alpha  | Beta | Cap(B) |
|------------|---------|-------|--------|------|--------|
| 2015-2017  | 26.0%   | 66.8%  | -2.0%  | -0.1 | 336.6  |
| 2016-2018  | 14.0%   | 10.7%  | -1.0%  | 0.1  | 310.9  |
| 2017-2019  | 20.0%   | 71.5%  | -2.0%  | 0.4  | 351.4  |
| 2018-2020  | 19.0%   | 79.2%  | -4.0%  | 0.4  | 379.2  |
| 2019-2021  | 33.0%   | 79.2%  | -14.0% | 0.5  | 412.2  |
| 2020-2022  | 8.0%    | 79.6%  | 9.0%   | 0.4  | 425.6  |
| 2021-2023  | -19.0%  | 79.6%  | -20.0% | 0.3  | 377.6  |
| 2022-2024  | -32.0%  | 79.6%  | -53.0% | 0.3  | 348.4  |
| 2023-2025  | 32.0%   | 79.6%  | -32.0% | 0.1  | 501.9  |

*   **CAGR (Compound Annual Growth Rate):** The average annual growth rate of an investment over a specified period of time, assuming profits are reinvested during the term.
*   **MDD (Maximum Drawdown):** The largest peak-to-trough decline during a specific period.  It's a measure of downside risk.  High MDD suggests significant potential losses.
*   **Alpha:** A measure of performance on a risk-adjusted basis.  Positive alpha indicates the investment has performed better than expected for the risk taken. Negative means it underperformed.
*   **Beta:** A measure of a stock's volatility relative to the market. Beta < 1 means less volatile than the market. Beta > 1 means more volatile.
*   **Cap(B):**  Market Capitalization in Billions.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 208.31
*   **Previous Close:** 210.33
*   **Change:** -0.96
*   **5-day SMA:** 210.738
*   **20-day SMA:** 206.296
*   **60-day SMA:** 195.3537

**Analysis:**

*   The stock price experienced a slight decrease in the most recent trading session.
*   The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA. This *could* suggest a short-term uptrend, but it's important to consider other factors.
*   The fact that the 20-day SMA is above the 60-day SMA can signal an uptrend. However, the recent price decline and the 5-day SMA being above the 20-day SMA warrants caution.

**3) Technical Indicators & Expected Return**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 52.13 (Neutral - neither overbought nor oversold)
*   **PPO (Percentage Price Oscillator):** -0.0426 (Slightly bearish, indicating the short-term moving average is below the long-term moving average)
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent (20 days) relative divergence change:** 10.2 (+): 단기상승 (Short-term increase)
*   **Expected Return (%):** -48.4 (Expected *negative* excess return compared to S&P 500)

**Analysis:**

*   The MRI suggests a medium investment recommendation.
*   The RSI indicates a neutral market sentiment towards JNJ.
*   The PPO, while slightly negative, doesn't present a strong bearish signal.
*   The Hybrid Signal is signaling a buy recommendation but with 0% cash.
*   The recent increase in relative divergence is a positive sign.
*   The extremely negative expected return is a *major* red flag. It suggests that, based on current data, JNJ is projected to significantly underperform the S&P 500 over the long term.

**4) Recent News & Significant Events**

*   **Positive FDA News (Dec 17, 2025):**  May have contributed to a short-term price increase.
*   **Valuation Perspectives (Nov 25, 2025):**  Indicates ongoing discussion and analysis of JNJ's value.
*   **Reason for Surge (Nov 21, 2025):**  Highlights a specific catalyst that drove stock price increase in November.
*   **Shares Sold by Thurston Springer Miller Herd & Titak Inc. (Dec 18, 2025):** News that a specific financial institution sold shares, which might reflect a lack of confidence in the stock.
*   **Key Levels And Resistance Levels (Dec 18, 2025):** Identifies the key levels to watch.
*   **Valuation Premium Justified By Accelerating Growth And Mix Premiumization (Dec 18, 2025):**  Contradicts the negative expected return, suggesting a potential for future growth and premium valuation.

**Analysis:**

*   Recent news is mixed, with positive FDA news and analysts justifying valuation, countered by news of share sales and discussion of valuation. The news suggests some optimism in JNJ's future growth potential, and others appear to be taking profit from those valuation claims.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean of 2.16)
*   **Target Price:** Average target of $208.17 (close to the current price).

**Analysis:**

*   The analyst consensus is generally positive, with a "Buy" rating. However, the average target price is near the current price, suggesting limited upside potential.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-10-22 | 1.12 | 22.47 B$ |

**Analysis:**

* There's a data error, with the Oct 22 entry duplicated.
* Revenue appears to be relatively consistent, with some fluctuations.
* EPS has varied significantly. The higher EPS in 2025-04-23 indicates a strong quarter, while the lower EPS in 2024-10-23/2025-10-22 suggest weaker performance in those periods.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $23.99B   | 69.56%        |
| 2025-06-30   | $23.74B   | 67.87%        |
| 2025-03-31   | $21.89B   | 66.40%        |
| 2024-12-31   | $22.52B   | 68.35%        |
| 2024-09-30   | $22.47B   | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30   | $79.28B   | 6.50% |
| 2025-06-30   | $78.47B   | 7.06% |
| 2025-03-31   | $78.11B   | 14.08% |
| 2024-12-31   | $71.49B   | 4.80% |
| 2024-09-30   | $70.16B   | 3.84% |

**Analysis:**

*   Revenue is generally stable, with a recent uptick in the most recent quarter.
*   Profit margins are consistently high, indicating strong profitability.
*   Equity is growing over time.
*   ROE (Return on Equity) fluctuates, with a spike in 2025-03-31. ROE is a measure of profitability relative to shareholders' equity.

**7) Comprehensive Analysis**

JNJ presents a mixed picture.

*   **Underperformance:** The stock has significantly underperformed the S&P 500, and the negative expected return is a serious concern. This underperformance is also reflected in the negative Alpha values.
*   **Financial Strength:** JNJ exhibits strong revenue, high profit margins, and growing equity, indicating financial stability.
*   **Technicals:** The technical indicators (RSI, PPO) are not providing strong buy or sell signals.
*   **Analyst Sentiment:** While analysts have a "Buy" consensus, the target price suggests limited upside.
*   **News & Events:** Recent news presents a mixed picture, with positives (FDA approval, valuation justification) balanced by negatives (share sales).
* **Warning:** MDD is very high, suggesting a substantial risk of losses.
*   **Warning:** the expected return is very negative and should be considered high risk.

**Overall Conclusion:**

The data suggests caution. While JNJ possesses financial strength, its underperformance relative to the market and the negative expected return are significant concerns. The analyst's buy consensus with limited upside suggests that the stock is accurately priced, and any excess return is unlikely to occur. There are possible signs of short-term recovery, but there are also financial risks to consider.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.